MBOT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Microbot Medical Inc. (MBOT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent FDA clearance for its LIBERTY system, positive analyst ratings, and unique market positioning as the only FDA-cleared robotic system for peripheral vascular procedures provide strong growth potential. While financials show losses, the company's early-stage commercialization and technological innovation outweigh the negatives for a long-term investor.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 78.919, which is in the neutral zone but approaching overbought levels. The pre-market price of $2.62 is above the pivot level of $2.304 and nearing resistance at $2.576, suggesting potential for further upward movement. Converging moving averages also indicate a potential trend shift.
FDA clearance for the LIBERTY system.
Launch of the LIBERTY system in Tampa General Hospital, marking market entry.
Positive analyst ratings with price targets of $5 and $5.50, indicating significant upside potential.
Unique positioning as the only FDA-cleared robotic system for peripheral vascular procedures.
Financial losses with negative EPS and net income.
High implied volatility (122.
and IV percentile (68.13), indicating elevated risk.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 11.26% YoY but remains negative at -$3,577,000. EPS dropped by 65% YoY to -0.07. The company is in an early commercialization phase, which explains the lack of revenue.
Two analysts initiated coverage with Buy ratings and price targets of $5 and $5.50. Analysts highlight the company's unique FDA-cleared technology, clinically validated benefits, and disposable model as strong competitive advantages.
